Current state of renal transplant immunosuppression: Present and future

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 4

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Guidelines for Clinical Practice

World J Transplant. Aug 24, 2012; 2(4): 51-68
Published online Aug 24, 2012. doi: 10.5500/wjt.v2.i4.51

Table 3 Non-food and drug administration approved/investigational agents and their mechanism

Name	Mechanism of action
Induction
Alemtuzumab	Monoclonal antibody, CD52
Efaluzimab	Humanized antibody, CD11a/LFA-1
Alefacept	Costimulation inhibitor, CD2 LFA3
Maintenance
Prolonged release tacrolimus	Calcineurin inhibitor
Voclosporin, ISA247	Calcineurin inhibitor
Mizoribine	Purine synthesis inhibitors
Sotrastaurin, AEB071	Protein kinase C inhibitor
Tofacitinib, CP-690550	JAK 3 inhibitor
Treatment of antibody medicated rejection
Bortezomib	Proteasome inhibitor
Eculizumab	Monoclonal antibody, C5 complement protein

Citation: Kalluri HV, Hardinger KL. Current state of renal transplant immunosuppression: Present and future. World J Transplant 2012; 2(4): 51-68
URL: https://www.wjgnet.com/2220-3230/full/v2/i4/51.htm
DOI: https://dx.doi.org/10.5500/wjt.v2.i4.51

Kalluri HV, Hardinger KL. Current state of renal transplant immunosuppression: Present and future. World J Transplant 2012; 2(4): 51-68 [PMID: 24175197 DOI: 10.5500/wjt.v2.i4.51]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.